Marc Steven Sabatine
Brigham and Women's Hospital
3 papers in the Anchorcite directory, published between 2017 and 2019, cited 20,486 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Cardiovascular Function and Risk Factors · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
- Lipoproteins and Cardiovascular Health · 1 paper
- Acute Myocardial Infarction Research · 1 paper
Frequent co-authors
- Anna-Maria Langkilde · 2 papers
- Stephen D. Wiviott · 2 papers
- Julia Kuder · 2 papers
- Sabina A. Murphy · 2 papers
- John J.V. McMurray · 1 paper
- Scott David Solomon · 1 paper
- Silvio E. Inzucchi · 1 paper
- Lars Køber · 1 paper
Papers
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine · 2017 · 6,357 citations
BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving…
Metadata from OpenAlex (CC0).